8/6/2019 Hypo Parathyroid Ism
1/39
A 30-year old male admitted with headache and generalized convulsions. His medical history is notable only for
thyroidectomy four years back . Fundi examination foundsB/L papilloedema and no focal neurological sign.Trousseau s sign is positive. BMI is 27 kg/ m 2. ECG shows QT interval of >50% of R-R interval. His total serum calcium is1.7 mmol/l. CT brain ( non contrast and contrast) is normal.
5/5/2011
8/6/2019 Hypo Parathyroid Ism
2/39
Hypoparathyroidism
Dr.Upul Pathirana
Registrar (Medicine)
5/5/2011
8/6/2019 Hypo Parathyroid Ism
3/39
Control of Mineral Metabolism by Parathyroid Hormone
Low serum Ca 2+sensed throughCaSRs
Parathyroidglands
Intestine
Bone
Kidney
Boneresorption
Increasedcalciumreabsorption,decreased
PO 4reabsorption
Increased Ca 2+and PO4into serum(normal rangerestored)
PTH
1 ,25 (OH)2D25 (OH)D
5/5/2011
8/6/2019 Hypo Parathyroid Ism
4/39
5/5/2011
8/6/2019 Hypo Parathyroid Ism
5/39
W hen the actions of PTH are reduced or lost
Hypocalcemia
Hyperphosphatemia,
Hypercalciuria
5/5/2011
8/6/2019 Hypo Parathyroid Ism
6/39
The Clinical Problem
Hypocalcemia
defined as low serum levels of albumin-corrected total calcium(normal range, 8. 5 to 10 .5 mg per deciliter [ 2 .1 to 2 .6 mmolper liter]) or of ionized calcium
5/5/2011
8/6/2019 Hypo Parathyroid Ism
7/39
Hypocalcemia
Viewed broadly inadequate parathyroid hormone (PTH) secretion or
receptor activation
insufficient supply of vitamin D or activity of thevitamin D receptor
abnormal magnesium metabolism
clinical situations in which multiple factors (e.g.,pancreatitis, sepsis, and critical illness)
5/5/2011
8/6/2019 Hypo Parathyroid Ism
8/39
Presentation
Neuromuscular symptoms are typically the most prominent muscle cramping, twitching, and spasms circumoral and acral numbness and paresthesias laryngospasm; bronchospasm seizures
Two signs Chvosteks sign Trousseau s sign
5/5/2011
8/6/2019 Hypo Parathyroid Ism
9/39
Severe hypocalcaemia
Cardiac function may beaffected, manifested by
prolonged QT interval
corrected for heart rate (QTc)
in rare cases, depressedsystolic function and heartfailure
5/5/2011
8/6/2019 Hypo Parathyroid Ism
10/39
Pseudortumor cerebri
Marked papilloedema
Neither a mass nor an increase in ventricular size
5/5/2011
8/6/2019 Hypo Parathyroid Ism
11/39
Pseudotumor cerebri
Modified Dandy criteria
1 Symptoms of raised intracranial pressure (headache, nausea, vomiting,transient visual obscurations, or papilledema)
2 No localizing signs with the exception of abducens (sixth) nerve palsy
3 The patient is awake and alert
4 Normal CT / MRI findings without evidence of thrombosis
5 LP opening pressure of > 25 cmH 2O and normal biochemical andcytological composition of CSF
6 No other explanation for the raised intracranial pressure
5/5/2011
8/6/2019 Hypo Parathyroid Ism
12/39
Hypoparathyroidism can be congenital or acquired
Acquired hypoparathyroidism is most commonly the
result of inadvertent removal or irreversible damage tothe glands, usually to their blood supply, duringthyroidectomy, parathyroidectomy, or radical neckdissection
Immune-mediated destruction of the parathyroid glandscan be either isolated or part of autoimmunepolyendocrine syndrome type 1 (APS-1)
5/5/2011
Hypoparathyroidism -Differential Diagnosis
8/6/2019 Hypo Parathyroid Ism
13/39
Hypoparathyroidism may also be caused by accumulation inthe parathyroid glands of iron (hemochromatosis or
transfusion-dependent thalassemia) or copper (W
ilson sdisease)or (in rare cases) by iodine- 131 therapy for thyroiddiseases or metastatic infiltration of the parathyroid glands bytumor
Magnesium depletion or excess may cause hypocalcemia byinducing functional hypoparathyroidism
5/5/2011
Hypoparathyroidism -Differential Diagnosis
8/6/2019 Hypo Parathyroid Ism
14/39
G enetic disorders must also be considered as a possible causeof hypocalcemia. (Di G eorge or velocardiofacial syndrome)
Inherited hypoparathyroidism and are manifested asautosomal dominant hypocalcemia at any age
Familial hypoparathyroidism due to dysgenesis of theparathyroid glands
5/5/2011
Hypoparathyroidism -Differential Diagnosis
8/6/2019 Hypo Parathyroid Ism
15/39
1 . Postsurgicalhypoparathyroidism
2 . Autoimmunehypoparathyroidism
3. Deposition of heavy metalsin parathyroid tissue
4. Radiation-induceddestruction of parathyroidtissue
5 . Metastatic infiltration of theparathyroid glands
6. Magnesium depletion orexcess
7. G enetic disorders / Inheritedhypoparathyroidism
8. Pseudohypoparathyroidism
5/5/2011
Hypoparathyroidism -Differential Diagnosis
8/6/2019 Hypo Parathyroid Ism
16/39
DiG eorge syndrome
Familial condition in which the hypoparathyroidism isassociated with
Intelectual impairment Cataract Calcified basal ganglia Occasionaly with specific autoimmune disease and
immune deficiencies
5/5/2011
8/6/2019 Hypo Parathyroid Ism
17/39
Pseudohypoparathyroidism
Syndrome of end-organ resistance to PTH ,it isassociated with
Short stature Short metacarpals Subcutaneous calcifications Intelectual impairment
5/5/2011
8/6/2019 Hypo Parathyroid Ism
18/39
Pseudo-pseudohypoparathyroidism
Phenotypic defects but without any abnormalities of calcium metabolism
5/5/2011
8/6/2019 Hypo Parathyroid Ism
19/39
Evaluation
Review of the patient s medical and family histories
A history of neck surgery
A family history of hypocalcemia (genetic cause)
autoimmune endocrinopathies (e.g., adrenal insufficiency) orcandidiasis prompts consideration of autoimmunepolyendocrine syndrome type 1 .
Immunodeficiency and other congenital defects point to theDiG eorge syndrome
5/5/2011
8/6/2019 Hypo Parathyroid Ism
20/39
Evaluation
Physical examination
neuromuscular irritability by testing for Chvostek s andTrousseau s signs
skin should be examined carefully for a neck scar (whichsuggests a postsurgical cause of hypocalcemia); for candidiasisand vitiligo (which are suggestive of APS- 1); and for generalizedbronzing and signs of liver disease (which are suggestive of
hemochromatosis)
Features such as growth failure, congenital anomalies, hearingloss, or retardation point to the possibility of genetic d isease
5/5/2011
8/6/2019 Hypo Parathyroid Ism
21/39
8/6/2019 Hypo Parathyroid Ism
22/39
Pseudohypoparathyroidism
Patients with pseudohypoparathyroidism have alaboratory profile that resembles that in patientswith hypoparathyroidism
(i.e., low calcium and high phosphorus levels),
but they have elevated PTH levels
5/5/2011
8/6/2019 Hypo Parathyroid Ism
23/39
Vitamin D deficiency
In classic vitamin D deficiency,
intact PTH levels are elevated,serum phosphorus levels are low or at the lowend of the normal range
(in marked contrast to the high levels in
hypoparathyroidism)
5/5/2011
8/6/2019 Hypo Parathyroid Ism
24/39
Treatment and Clinical Monitoring1 .Calcium therapy
The goals of therapy are to control symptoms while minimizingcomplications
Urgent care of patients with hypocalcemia should be guided by thenature and severity of the symptoms and the level of serum calcium
Severe symptoms (e.g., seizures, laryngospasm, bronchospasm, cardiacfailure, and altered mental status) warrant intravenous calcium
therapy, even if the serum calcium level is only mildly reduced (e.g.,7.0 to 8. 0 mg per deciliter [ 1 .75 to 2 .00 mmol per liter])
5/5/2011
8/6/2019 Hypo Parathyroid Ism
25/39
8/6/2019 Hypo Parathyroid Ism
26/39
Intravenous infusions are generally tapered slowly (over a period of 24to 48 hours or longer) while oral therapy is adjusted
Oral therapy is appropriate in patients with mildly reduced serum totalcalcium levels (7. 5 to 8. 0 mg per deciliter [ 1 .87 to 2 .00 mmol perliter]) who have symptoms, even if they are nonspecific ones (e.g.,fatigue, anxiety, and reduced well-being) because these symptomsmay improve with treatment
5/5/2011
Treatment and Clinical Monitoring
8/6/2019 Hypo Parathyroid Ism
27/39
Vitamin D metabolites and analogues are essential to the managementof hypoparathyroidism . The key complication to avoid is vitamin Dintoxication (hypercalcemia and hypercalciuria) with its adverseeffects on the renal and central nervous systems
Calcitriol is preferred (over vitamin D 2 or D3) because of its potencyand rapid onset and offset of action
Thiazide diuretics can be used to reduce (or prevent) hypercalciuriacaused by calcium and vitamin D therapy
5/5/2011
Treatment and Clinical Monitoring2 . Vitamin D therapy
8/6/2019 Hypo Parathyroid Ism
28/39
Treatment and Clinical Monitoring3.reduce hyperphosphataemia
Hyperphosphatemia may be addressed by minimizing thepatient s dietary intake of phosphate (e.g., in meats, eggs,
dairy products, and cola beverages) and,
If needed, with phosphate binders to control or prevent anunacceptable calcium phosphate product
5/5/2011
8/6/2019 Hypo Parathyroid Ism
29/39
Follow up
Levels of serum calcium, phosphorus, and creatinine should bemeasured weekly to monthly during initial dose adjustments,
with twice-yearly measurements once the regimen has beenStabilized
Urinary calcium and creatinine levels are measured twice yearlyto detect any renal toxic effects of hypercalciuria
5/5/2011
8/6/2019 Hypo Parathyroid Ism
30/39
The goals of therapy are symptom control, a serum albumincorrected total calcium level at the lower end of the normalrange (approximately 8. 0 to 8. 5 mg per deciliter [ 2 .00 to 2 .12 mmol per liter]), a 24- hour urinary calcium level well below300 mg, and a calcium phosphate product below 55
Annual slit-lamp and ophthalmoscopic examinations arerecommended to monitor for the development of cataracts inall patients
5/5/2011
Follow up
8/6/2019 Hypo Parathyroid Ism
31/39
???
There are no available data from clinical trials to show thatcomplications of chronic hypocalcemia are preventable with
aggressive therapy or that patients with mildly abnormalbiochemical findings derive benefits from therapy.
Clinical experience, however, indicates that patients with serumcalcium levels near the lower end of the normal range tend tofeel better, with less tetany, muscle cramps, and fatigue, thanthose with mild hypocalcemia who are not treat
5/5/2011
8/6/2019 Hypo Parathyroid Ism
32/39
Areas of Uncertainty
Hypoparathyroidism is one of the few endocrinopathies for whichhormone-replacement therapy is not readily available
Only a few small, randomized trials have assessed the use of injectablehuman PTH in patients with this condition
Limited data suggest that the quality of life may be compromised inpatients with hypoparathyroidism despite treatment to optimize
their biochemical values
The effect of PTH replacement on quality-of-life measures is notknown.
5/5/2011
8/6/2019 Hypo Parathyroid Ism
33/39
G uidelines
There are no formal guidelines for the management of hypoparathyroidism
5/5/2011
8/6/2019 Hypo Parathyroid Ism
34/39
Conclusions and Recommendations
The initial evaluation of a patient withhypocalcemia should include adetailed family history (which may suggest a genetic cause) andrelevant medical history (particularly regarding neck surgery andautoimmune disease).
Laboratory testing should include measurements of serum total andionized calcium, albumin, phosphorus, magnesium, and intact PTHlevels
If the patient has severe symptoms, therapy with intravenous calciumshould be initiated immediately, and the diagnosis pursued afterthe patient s condition has been stabilized
5/5/2011
8/6/2019 Hypo Parathyroid Ism
35/39
Reference
The new england journal of medicine
( N Engl J Med 200 8;3 59: 391 -403)
5/5/2011
8/6/2019 Hypo Parathyroid Ism
36/39
Thank You
5/5/2011
8/6/2019 Hypo Parathyroid Ism
37/39
5/5/2011
8/6/2019 Hypo Parathyroid Ism
38/39
5/5/2011
8/6/2019 Hypo Parathyroid Ism
39/39
5/5/2011